66th ASH Annual Meeting: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I

Symposia: Myelodysplastic Syndromes: Clinical and Epidemiological Oral and Poster Abstracts
Poster

MDS, Research, Artificial intelligence (AI), Acute Myeloid Malignancies, Combination therapy, AML, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Drug development, Translational Research, Epidemiology, Genomics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Clinical Research, Health outcomes research, Chronic Myeloid Malignancies, CMML, Hematopoiesis, Pediatric, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Real-world evidence, Adverse Events, Non-Biological therapies, Metabolism, Myeloid Malignancies, Biological Processes, Emerging technologies, Monoclonal Antibody Therapy, Technology and Procedures, Molecular biology, Study Population, Human, Measurable Residual Disease , Machine learning, Molecular testing

Halls G-H (San Diego Convention Center)

1818

Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial

Valeria Santini¹^*, Amer M. Zeidan, MBBS, MHS², Uwe Platzbecker, MD³, Rami S. Komrokji, MD⁴, Guillermo Garcia-Manero, MD⁵, Dimana Miteva⁶^*, Aylin Yucel⁷^*, Veronika Pozharskaya⁷^*, Shelonitda Rose⁷, Yinzhi Lai⁷^*, Ana Carolina Giuseppi⁷^*, David Valcárcel Ferreiras⁸^*, Pierre Fenaux, MD⁹, Jake Shortt¹⁰^* and Matteo Giovanni Della Porta, MD¹¹^*

¹University of Florence Medical School, Florence, Italy
²Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
³University Hospital Leipzig, Leipzig, Germany
⁴Moffitt Cancer Center, Tampa, FL
⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Bristol Myers Squibb, Boudry, Switzerland
⁷Bristol Myers Squibb, Princeton, NJ
⁸Hospital Vall d'Hebron, Barcelona, Spain
⁹Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
¹⁰Monash University and Monash Health, Melbourne, VIC, Australia
¹¹Humanitas University, Milan, Italy

1819

Sandra Huber, PhD¹, Stephan Hutter, PhD¹^*, Constance Regina Baer, PhD¹, Manja Meggendorfer, PhD², Gregor Hoermann, MD, PhD², Wolfgang Kern, MD¹, Torsten Haferlach, MD¹ and Claudia Haferlach, MD¹

¹MLL Munich Leukemia Laboratory, Munich, Germany
²MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

1820

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Clifford M. Csizmar, MD, PhD¹, Anuya A. Natu, MBBS¹^*, Mark Gurney, MB, BCh, BAO¹^*, Rashmi Kanagal-Shamanna, MD², Sanam Loghavi, MD³, Alexandre Bazinet, MD⁴^*, Kelly S. Chien, MD⁵, Danielle Hammond, MD⁶, Terra L. Lasho, PhD⁷, Christy Finke, BS¹^*, Aref Al-Kali, MD¹, Hassan B Alkhateeb, MD¹^*, Naseema Gangat, MBBS¹, Abhishek A. Mangaonkar, MBBS⁷, Antoine N. Saliba, MD¹, Ayalew Tefferi, MD¹, Guillermo Garcia-Manero, MD⁶, Hagop Kantarjian, MD⁶, Guillermo Montalban-Bravo, MD⁶ and Mrinal M. Patnaik, MD, MBBS¹

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
⁵Department of Leukemia, MD Anderson, Houston, TX
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Mayo Clinic, Rochester, MN

1821

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, MD¹, Hetty E. Carraway, MD, MBA², Richard M Stone, MD³, Yazan F Madanat, MD⁴, Rami S. Komrokji, MD⁵, Sangeetha Venugopal, MD, MS⁶, Namrata S. Chandhok, MD⁷, Terrence Bradley, MD⁸, Justin Taylor, MD⁹, Anastasia Santiago, NP⁶, Alessia Zoso, PhD¹⁰^*, Justin M. Watts, MD¹¹ and Amy E. DeZern, MD¹²

¹Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL
²Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX
⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Sylvester Cancer Center, University of Miami, Miami, FL
⁷Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, FL
⁸University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
⁹Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
¹⁰University of Miami Sylvester Cancer Center, Miami, FL
¹¹Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL
¹²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

1822

Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms

Freya Schulze, MD¹^*, Waldemar Hahn, MSc^2,3^*, Katja Sockel, MD¹^*, Susann Winter, PhD¹^*, Markus Wolfien, PhD^2,3^*, Martin Bornhaeuser, MD^4,5,6, Jan Moritz Middeke, MD^1,7^* and Jan-Niklas Eckardt^1,7^*

¹Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
²Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Dresden, Germany
³Institute for Medical Informatics and Biometry, TUD Dresden University of Technology, Dresden, Germany
⁴Department of Internal Medicine I, Universitatsklinikum Cad GustavCarus an der Technischen Universltat Dresden, Dresden, Ferscherstrabo 74, Germany
⁵National Center for Tumor Disease (NCT), Dresden, Germany
⁶German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Dresden, Germany
⁷Else Kroener Fresenius Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany

1823

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Talha Badar, MD¹, Kashish J. Shah, MBBS²^*, Mobachir El Kettani, MD²^*, James M. Foran, MD³, Mohamed A. Kharfan-Dabaja, MD, MBA⁴, Hemant S. Murthy, MD², Naseema Gangat, MBBS⁵, Aref Al-Kali, MD⁶, Mithun V Shah, M.D., Ph.D.⁵, Hassan B Alkhateeb, MD⁵^*, Antoine N. Saliba, MD⁵, William J. Hogan, MD⁵, Cecilia Y. Arana Yi, MD⁷, Lisa Sproat, MD⁸, Jeanne Palmer, MD⁹, Mark R. Litzow, MD⁵ and Mrinal M. Patnaik, MD, MBBS¹⁰

¹Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL
²Mayo Clinic, Jacksonville, FL
³Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
⁴Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
⁵Division of Hematology, Mayo Clinic, Rochester, MN
⁶Mayo Clinic, Rochester
⁷Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
⁸Mayo Clinic, Phoenix, AZ
⁹Mayo Clinic - Arizona, Scottsdale, AZ
¹⁰Mayo Clinic, Rochester, MN

1824

Single-Tube Flow Cytometry 12-Color Combination for the Screening, Classification, and Staging of Chronic Myelomonocytic Leukemia. Correlation with NGS Molecular Data

Paula Piñero, PhD¹^*, Rocio Gonzalez²^*, Vanesa Diaz³^*, Elena Marin⁴^*, Marina Gonzalez⁴^*, Javier Lopez⁴^*, Pablo Manresa³^*, M. Carmen Garcia Hernandez⁵^* and Fabian Tarin³^*

¹ISABIAL, ALICANTE, AL, Spain
²ISABIAL, ALICANTE, Spain
³Hospital Universitario Dr. Balmis, ALICANTE, Spain
⁴PINTOR BAEZA 12, Hospital Universitario Dr. Balmis, ALICANTE, Spain
⁵Hospital Universitario Dr. Balmis, Alicante, Spain

1825

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Aristoteles Giagounidis, MD¹, Monteserrat Arnan, MD, PhD²^*, Lynette C.Y. Chee, MBBS, PhD, FRACP, FRCPA³, Thomas Cluzeau, MD, PhD⁴, Maria Diez-Campelo, MD, PhD⁵^*, Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA⁶, David M Ross, MD, PhD, FRACP, FRCPA⁷^*, Mikkael A. Sekeres, MD⁸, Shuhying Tan, FRACP, FRCPA, MBBS⁹^*, David Valcarcel, MD, PhD¹⁰, Rena Buckstein, MD, FRCPC¹¹, Bhavna Patel-Shah¹²^*, Ming Yang, PhD¹²^*, Ying Jiang, PhD, MBA¹²^*, Jiani Yin, PhD¹²^*, Suresh Bobba¹²^*, Montagu Hankin, MSc¹²^*, Chris Materna, MSc¹²^*, Christine Graham, PhD¹²^*, Sanjay Thamake, PhD, MBA¹²^*, Christopher Rovaldi, MSc¹²^*, Dena Grayson, MD, PhD¹²^* and Jen L. Salstrom, MD, PhD¹²

¹Clinic for Hematology, Oncology and Palliative Care Marien Hospital Düsseldorf, Dusseldorf, Germany
²Institut Català d'Oncologia -Hospital Duran i Reynalshe, Ashby De La Zouch, ESP
³Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Australia
⁴Department for Clinical Hematology, Nice University Hospital, Nice, Provence Alpes Cote d'Azur, France
⁵Hospital Clínico Universitario de Salamanca, Salamanca, Spain
⁶Royal Adelaide Hospital, Adelaide, SA, Australia
⁷Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
⁸Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
⁹Department of Haematology, St Vincent’s Hospital, Melbourne, Australia
¹⁰Department of Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
¹¹Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
¹²Kero's Therapeutics, Lexington

1826

A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Mathieu Meunier¹^*, Sylvain Thepot, MD²^*, Stanislas Nimubona, MD³^*, Mélanie Véloso⁴^*, Thibaud Lefebvre⁵^*, Karim Zoubida⁶^*, Martine Ropert-Bouchet⁷^*, Frederic Garban, Md, PhD⁸^*, Shanti Ame, MD, PhD⁹^*, Abdesssamia Gandoul¹⁰^*, Claire Reynes¹¹^*, Celia Salanoubat¹²^*, Sébastien Maury, MD, PhD¹³^*, Kamel Laribi, MD¹⁴^*, Pirayeh Eftekhari¹⁵^*, Jacques Delaunay¹⁶^*, Geoffroy Venton¹⁷^*, Clemence Santana¹⁸^*, Stephane Cheze, MD¹⁹^*, Sophie Dimicoli-Salazar, MD²⁰^*, Mathieu Molimard²¹^*, Valérie Rolland-Neyret²²^*, Sandra David-Tchouda^23,24,25^* and Sophie Park, MD, PhD²⁶

¹Department of Hematology CHU Grenoble Alpes, Grenoble, France
²Department of Clinical Hematology, Angers University Hospital, ANGERS, NA, France
³Hopital Pontchaillou, Rennes, France
⁴Data Engineering Unit, Public Health Department,, Univ. Grenoble Alpes and Grenoble Alpes University Hospital,, Grenoble, France
⁵Centre Français des Porphyries, INSERM U1149,, Hôpital Louis Mourier, APHP, Colombes, France
⁶Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity),INSERM UMR1291 - CNRS UMR5051, Université Toulouse III, CHU PURPAN, Toulouse, France
⁷Laboratoire de biochimie spécialisée, CHU de Rennes, Rennes,, France
⁸Hematology Department, CHU Grenobles Alpes, Grenoble, France
⁹Department of hematology, Institut de Cancérologie de Strasbourg, Strasbourg, France
¹⁰Hematology Department, CHU Grenoble Alpes, Grenoble, France
¹¹Hematology Unit, Annecy Genevois Hospital Center, Annecy, France
¹²Hématologie clinique, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
¹³Hematology Department, Hôpital Henri Mondor, Créteil, France
¹⁴Hematology Department, Le Mans Hospital, Le Mans, France
¹⁵Department of Hematology, AP-HP. Hôpital Bicêtre, Paris, France
¹⁶Hôpital privé du confluent, Nantes, France
¹⁷Hôpital de la Timone, Service Hématologie et Thérapie Cellulaire, Centre d’Essais Précoces en Cancérologie de Marseille (CEPCM), Marseille, France
¹⁸département d'hématologie, CH de Valence, Valence, France
¹⁹Institut d'Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France
²⁰Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
²¹Department of Medical Pharmacology, CHU de Bordeaux, Bordeaux, France
²²Department of Hematology, CHU Grenoble Alpes, Grenoble, France
²³Data Engineering Unit, Public Health Department,, Univ. Grenoble Alpes and Grenoble Alpes University Hospital, Grenoble, France
²⁴Clinical and economic unit, Public Health Department, Grenoble Alpes University Hospital, Grenoble, France
²⁵TIMC-Imag UMR 5525, Univ. Grenoble Alpes, Grenoble, France
²⁶Hematology Department, CHU Grenoble, Grenoble Cedex 9, France

1827

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Ayalew Tefferi, MD¹, Saubia Fathima²^*, Ali Khalid Alsugair³^*, Clifford M. Csizmar, MD, PhD⁴, Mark Gurney, MB, BCh, BAO¹^*, Terra L. Lasho, PhD², Christy Finke, BS¹^*, Abhishek A. Mangaonkar, MBBS², Aref Al-Kali, MD³, Hassan B Alkhateeb, MD¹^*, Kaaren K. Reichard, MD⁵, Animesh D. Pardanani, MBBS, PhD⁴, Naseema Gangat, MBBS¹ and Mrinal M. Patnaik, MD, MBBS²

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Mayo Clinic, Rochester, MN
³Mayo Clinic, Rochester
⁴Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
⁵Department of Pathology, Mayo Clinic, Rochester, MN

1828

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Daniel A Pollyea, MD¹, Brett M Stevens, PhD, BS²^*, Diana Abbott, PhD³, Maria L Amaya, MD, PhD^4,5, Jonathan Gutman, MD⁶, Andrew Kent, MD, PhD⁶, Christine M. McMahon, MD⁷, Marc Schwartz, MD¹, Clayton Smith, MD⁸, Jessica Dell-Martin⁹^*, Connor Sohalski⁴^*, Alexandra Ellis¹⁰^*, Mary Haag¹⁰^*, Jeffrey Schowinsky⁴^*, Zenggang Pan, MD, PhD¹¹^*, Sweta B Patel, PhD¹²^*, Monica Ransom, PhD¹²^*, Austin E Gillen, PhD²^*, Eric M. Pietras, PhD¹³ and Craig T Jordan, PhD¹⁴

¹Division of Hematology, University of Colorado, Denver, CO
²Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO
³Center for Innovative Design and Analysis (CIDA), Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO
⁴University of Colorado, Aurora, CO
⁵Rocky Mountain Regional VA Medical Center, Aurora, CO
⁶Division of Hematology, University of Colorado, Aurora, CO
⁷University of Colorado School of Medicine, Denver, CO
⁸CU Innovations, University of Colorado, Aurora, CO
⁹University of Colorado Anschutz Medical Campus, Aurora, CO
¹⁰University of Colorado, Aurora
¹¹Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO
¹²University of Colorado School of Medicine, Aurora, CO
¹³Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
¹⁴Universit of Colorado Anschutz Medical Campus, Aurora, CO

1829

Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Nina Kim^*, Xin Wang, PhD^*, Ilynn Bulatao, MD, PhD^*, Jonathon Vallejo, PhD^*, Yuan Li Shen, PhD^*, Dianne D. Pulte, MD, Marc R. Theoret, MD^*, R. Angelo De Claro, MD^* and Kelly J. Norsworthy, MD^*

U.S. Food and Drug Administration, Silver Spring, MD

1830

Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count

Curtis A Lachowiez, MD¹, Georgios Asimomitis²^*, Elsa Bernard, PhD³^*, Yanis Tazi, MSc, BSc⁴^*, Maria Creignou, MD⁵^*, Ulrich Germing, MD⁶^*, Norbert Gattermann, MD⁷, Amanda Gilkes, PhD⁸^*, Ian Thomas⁹^*, Lars Bullinger¹⁰, Konstanze Döhner, MD¹¹, Luca Malcovati, MD¹², Nigel H. Russell, MD¹³, Mario Cazzola, MD¹⁴, Hartmut Döhner, MD¹¹, Brian J P Huntly, MD¹⁵^*, Robert P Hasserjian, MD¹⁶, Eva Hellstrom Lindberg, MD, PhD¹⁷^*, Sanam Loghavi, MD¹⁸ and Elli Papaemmanuil¹⁹

¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, Memorial Sloan Kettering Cancer Center, New York, NY
³Gustave Roussy, université Paris-Saclay, Inserm U981, Villejuif, France
⁴Memorial Sloan Kettering Cancer Center, New York
⁵Phase 1 Unit, Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden
⁶Department of Hematology, Oncology and Clinical Immunology, University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany
⁷Heinrich-Heine-Universitat, Dusseldorf, Germany
⁸Department of Haematology, Division of Cancer & Genetics School of Medicine, Cardiff University, Cardiff, United Kingdom
⁹Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
¹⁰Department of Hematology, Oncology, and Cancer Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
¹¹Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
¹²Department of Molecular Medicine, University of Pavia, Piazzale Golgi 2, Italy
¹³Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
¹⁴University of Pavia, Pavia, Italy
¹⁵Department of Haematology, University of Cambridge, Cambridge, United Kingdom
¹⁶Department of Pathology, Massachusetts General Hospital, Boston, MA
¹⁷Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
¹⁸Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁹Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

1831

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Amy E. DeZern, MD¹, Michael Otterstatter, PhD²^*, Nancy Gillis, PhD³, Gregory A Abel, MD, MPH⁴, Tareq Al Baghdadi, MD⁵^*, Rafael Bejar, MD, PhD⁶, H. Joachim Deeg, MD⁷, James M. Foran, MD⁸, Rami S. Komrokji, MD⁹, R. Coleman Lindsley, MD⁴, Jane Jijun Liu¹⁰^*, Lynn C. Moscinski, MD¹¹, Wael Saber, MD, MS¹², Ling Zhang, MD¹³, Christine Borchert, BSc²^*, Eric Padron, MD⁹, Seth Sherman, PhD²^*, Nancy DiFronzo, PhD¹⁴^*, Matthew J. Walter, MD¹⁵ and Mikkael A. Sekeres, MD¹⁶

¹The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
²The Emmes Company, LLC, Rockville, MD
³Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵IHA Hematology Oncology Consultants, Ypsilanti, MI
⁶University of California, San Diego, La Jolla, CA
⁷Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
⁹Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁰Illinois CancerCare, Peoria, IL
¹¹Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹²Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
¹³Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer and Research Institute, Tampa, FL
¹⁴Division of Blood Diseases & Resources, The National Heart, Lung, and Blood Institute, Bethesda, MD
¹⁵Washington University In St. Louis, Saint Louis, MO
¹⁶Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

1832

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Guillermo Garcia-Manero, MD¹, Matteo Giovanni Della Porta, MD^2,3^*, Valeria Santini⁴^*, Amer M. Zeidan, MBBS, MHS⁵, Rami S. Komrokji, MD⁶, Pierre Fenaux, MD⁷, David Valcárcel⁸, Jake Shortt⁹^*, Mrudula B. Glassberg¹⁰^*, Aylin Yucel¹¹^*, Yinzhi Lai¹¹^*, Dimana Miteva¹²^*, Shelonitda Rose¹¹, Ahmed Hnoosh¹³^* and Uwe Platzbecker, MD¹⁴

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy
³Department of Biomedical Sciences, Humanitas University, Milan, Italy
⁴MDS Unit, Hematology, University of Florence, DMSC, AOUC, Florence, Italy
⁵Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT
⁶Moffitt Cancer Center, Tampa, FL
⁷Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
⁸Vall d’Hebron Institute of Oncology (VHIO), Department of Hematology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
⁹Monash University and Monash Health, Melbourne, VIC, Australia
¹⁰Bristol Myers Squibb, Madison, NJ
¹¹Bristol Myers Squibb, Princeton, NJ
¹²Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
¹³Bristol Myers Squibb, Uxbridge, United Kingdom
¹⁴Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

1833

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, MD¹, Yiwen Liu, MS²^*, Jacqueline S. Garcia, MD³, Lourdes Mendez, MD⁴^*, Catherine Gutierrez, MD, PhD⁵, Philip C. Amrein, MD⁶, Rupa Narayan, MD⁶, Rahul Vedula, MD⁷, Donna S. Neuberg, ScD⁸, Marcio Andrade-Campos⁹^*, Simon Smith, PhD, BSc¹⁰^*, Richard M Stone, MD³, Amir T. Fathi, MD¹¹, Matthew J. Walter, MD¹², Timothy Aaron Graubert, MD⁶ and Meagan Jacoby, MD¹³

¹Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
²Data Science, Dana-Farber Cancer Institute, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, New Haven, CT
⁵Massachusetts General Hospital, Boston, MA
⁶Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA
⁷Medical Oncology, Dana-Farber Cancer Institute, Stoneham, MA
⁸Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁹Astrazeneca, Cambridge, GBR
¹⁰AstraZeneca, Royston, GBR
¹¹Center for Leukemia, Massachusetts General Hospital Cancer Center, Boston, MA
¹²Washington University In St. Louis, Saint Louis, MO
¹³Washington University-School of Medicine, Richmond Heights, MO

1834

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Wei-Bin Wu¹^*, Ya-Wen Luo²^*, Siqi Li, M.D.³^*, Lanping Xu⁴^*, Yu Wang⁵^*, Xiaohui Zhang, MD⁵, Yuqian Sun⁶^*, Feifei Tang⁷^*, Xiaodong Mo⁸^*, Kai-Yan Liu, MD, PhD⁹, Xiao-Su Zhao¹⁰^*, Xiang-Yu Zhao¹^*, He-Bing Chen²^*, Ying-Jun Chang¹¹^* and Xiaojun Huang¹²

¹Peking University People's Hospital, National Clinical Research Center For Hemat, Beijing, CHN
²Academy of Military Medical Sciences, Beijing, China
³Department of Hematology, Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
⁴Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China
⁵Peking University People's Hospital, Beijing, China
⁶National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
⁷Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, AL, China
⁸Peking University Institute of Hematology, Peking University Peoples’ Hospital, Beijing, China
⁹Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
¹⁰Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
¹¹Peking University PeopleS Hospital & Peking University Institute of Hema, Beijing, China
¹²Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China

1835

Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?

Beatrice Drexler, MD^1,2^*, Stephan Schwarz-Furlan³^*, Irith Baumann⁴^*, Martina Rudelius, MD⁵^*, Peter Noellke, MPH⁶^*, Dirk Lebrecht⁶^*, Senthilkumar Ramamoorthy, PhD⁶^*, Natalia Rotari²^*, Axel Karow⁷^*, Shinsuke Hirabayashi, M.D., Ph.D.⁸^*, Marcin Wlodarski, MD, PhD^2,9, Fabian Beier, MD¹⁰^*, Yvonne Lisa Behrens¹¹^*, Gudrun Göhring¹²^*, Reinhard Kalb¹³^*, Brigitte Strahm, PhD²^*, Miriam Erlacher¹⁴, Charlotte Marie Niemeyer, MD¹⁵ and Ayami Yoshimi²^*

¹Department of Hematology, University Hospital Basel, Basel, Switzerland
²Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University Medical Center Freiburg, Germany, Freiburg, Germany
³Institute of Pathology, Klinikum Kaufbeuren-Ravensburg, Kaufbeuren, Germany
⁴Klinikum Kaufbeuren-Ravensburg, Kaufbeuren, Germany
⁵Institute of Pathology, Hospital of the Ludwig-Maximilians-University (LMU), Munich, Germany
⁶Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University Medical Center Freiburg, Germany, Freiburg, DEU
⁷Friedrich-alexander-universitäT Erlangen-nüRnberg (FAU), Erlangen, DEU
⁸Department of Pediatrics, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
⁹St. Jude Children's Research Hospital, Memphis, TN
¹⁰University Hospital Aachen, Aachen, NRW, Germany
¹¹Hannover Medical School, Hannover, DEU
¹²Amedes Genetics, Hannover Medical School, Hannover, Germany
¹³University of Wuerzburg, Wuerzburg, DEU
¹⁴Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany
¹⁵Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University Medical Center Freiburg, Germany, Freiburg, Baden Württemberg, Germany

1836

Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53

Claudia Haferlach, MD¹, Sandra Huber, PhD¹, Stephan Hutter, PhD¹^*, Constance Regina Baer, PhD¹, Manja Meggendorfer, PhD², Gregor Hoermann, MD, PhD², Wolfgang Kern, MD¹ and Torsten Haferlach, MD¹

¹MLL Munich Leukemia Laboratory, Munich, Germany
²MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

1837

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Danielle Hammond, MD¹, Koji Sasaki, MD¹, Koichi Takahashi, MD, PhD¹, Elizabeth J. Shpall, MD², Uday Popat, MD², Betul Oran, MD, MS², Gheath Al-Atrash, MD, PhD²^*, Krina K. Patel, MD, MSc³, Jason R. Westin, MD⁴, Sattva S. Neelapu, MD⁵, Yesid Alvarado Valero, MD¹, Kelly S. Chien, MD⁶, Naval Daver, MD⁷, Guillermo Montalban-Bravo, MD¹, Abhishek Maiti, MBBS¹, Musa Yilmaz, MD¹, Elias Jabbour, MD⁸, Naveen Pemmaraju, MD⁹, Mahesh Swaminathan, MD¹, Jo Ishizawa, MD, PhD¹⁰, Nitin Jain, MD¹, Alessandra Ferrajoli, MD¹, Farhad Ravandi, MBBS¹¹, Steven M. Kornblau, MD¹, Gautam Borthakur, MD¹⁰, Guillermo Garcia-Manero, MD¹, Hagop M. Kantarjian, MD¹, Patrick K. Reville, MD, MPH¹ and Hussein A. Abbas, MD, PhD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
³M.D. Anderson Cancer Center, MD Anderson Cancer Center, Houston, TX
⁴The University of Texas M D Anderson Cancer Center, Houston, TX
⁵Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, MD Anderson, Houston, TX
⁷MD Anderson Cancer Center, Houston, TX
⁸Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
⁹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
¹⁰Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

1838

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Elena Bechtold Javier, MD¹^*, Helena Pomares¹^*, Sandra Castaño-Díez, MD²^*, Guillermo Ramil López, MD³^*, Ivan Martín, MD⁴^*, Ana Perez Gonzalez, MD⁵^*, Blanca Xicoy, MD⁶^*, Joan Bargay⁷^*, Ferran Vall-Llovera Calmet, MD⁸^*, Tzu Hua Chen, MD⁹^*, Jordi Vila Bou¹⁰^*, Clara Maluquer Artigal, MD¹^*, Ines Zugasti²^*, Mercedes Galiano¹^*, Shiomara Quiñones, MD¹^*, Mar Tormo, MD¹¹, Guadalupe Onate, MD, PhD³^*, Esther Alonso¹²^*, Neus Ruiz Xiville, PhD¹³^*, Lurdes Zamora, PhD¹⁴^*, Jordi Esteve, MD, PhD², Marina Diaz Beya, MD²^*, Anna Sureda Balari, MD, PhD¹ and Montserrat Arnan, MD, PhD¹^*

¹Clinical Hematology Department, ICO-Hospitalet, Hospital Durán i Reynals. IDIBELL, Barcelona., Barcelona, Spain
²Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain
³Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
⁴Department of Hematology and Medical Oncology, Hospital Clínico Universitario INCLIVA Biomedical Research Institute, Valencia, Spain, Valencia, Spain
⁵Department of Hematology, Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Barcelona, Spain
⁶Hematology Service, ICO-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
⁷Hematology Department, Hospital Universitario Son Llàtzer. IdIsBa., Palma de Mallorca, Spain
⁸Hematology Department, Hospital La Mutua. Tarrassa, Terrassa, ESP
⁹Hematology and Medical Oncology Department, University Hospital Morales Meseguer. CRH-IMIB, Murcia, Spain
¹⁰Institut Català d’Oncologia - Hospital Universitari de Girona Dr. Josep Trueta, Girona, ESP
¹¹Department of Hematology and Medical Oncology,, Hospital Clínico Universitario de Valencia. INCLIVA Biomedical Research Institute, Valencia, Spain
¹²Hospital De Bellvitge, L'Hospitalet De Llobregat, Ba, ESP
¹³Hematology Laboratory, ICO-Badalona, Hospital Germans Trias i Pujol., Badalona, Spain
¹⁴Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

1839

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Marie Sebert, MD, PhD¹^*, Sylvie Chevret²^*, Sophie Dimicoli-Salazar, MD³^*, Thomas Cluzeau, MD, PhD⁴^*, Odile Rauzy, MD⁵^*, Aspasia Stamatoulas Bastard, MD⁶^*, Kamel Laribi⁷^*, Gaelle Fossard⁸^*, Sylvain Thépot, MD^9,10^*, Silke Gloaguen, MSc¹¹^*, Kristell Desseaux¹²^*, Norbert Vey, MD¹³, Pierre Peterlin¹⁴^*, Anne-Laure Taksin¹⁵^*, Caroline Lejeune¹⁶^*, Sophie Park, MD, PhD¹⁷, Anne Banos, MD¹⁸^*, Aristoteles Giagounidis, MD¹⁹, Emmanuel Gyan, MD, PhD²⁰, Mario Ojeda-Uribe, MD²¹^*, Stefanie Groepper, MD²²^*, Fatiha Chermat²³^*, Emmanuelle Clappier, Pharm.D., Ph.D.²⁴^*, Uwe Platzbecker, MD²⁵, Pierre Fenaux, MD²⁶ and Lionel Ades, MD, PhD²⁷

¹Hematology department, Saint-Louis Hospital, Paris, France
²Biostatistics and Medical Information Department, Saint Louis Hospital, Assistance Publique — Hôpitaux de Paris (AP-HP), Paris, France
³Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
⁴Centre Hospitalier Universitaire de Nice, Nice, France
⁵Department for Internal Medicine, Toulouse University Hospital, Toulouse, France
⁶Centre Henri Becquerel, Rouen, FRA
⁷Hématologie Clinique, CH Le Mans, Le Mans, France
⁸Department of Hematology, Lyon Sud Hospital, Pierre Benite, FRA
⁹Service des Maladies du Sang, CHU Angers, Angers, France
¹⁰Centre Hospitalier Universitaire d'Angers, Angers, France
¹¹GWT-TUD Gmbh, Dresden, Sachsen, DEU
¹²Department of Biostatistics and Medical Informatics,, Hôpital Saint Louis, GHU AP-HP Nord Université Paris Cité, Paris, FRA
¹³Department of Hematology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille, France
¹⁴Hematology Department, Hôtel-Dieu University Hospital, NANTES CEDEX 1, France
¹⁵CHu de Versailles, Versailles, France
¹⁶Hematology department, ICLN, CHU Saint-Etienne, Saint etienne, France
¹⁷Hematology Department, CHU Grenoble, Grenoble Cedex 9, France
¹⁸Centre Hospitalier De Bayonne, Bayonne, FRA
¹⁹Clinic for Hematology, Oncology and Palliative Care Marien Hospital Düsseldorf, Dusseldorf, Germany
²⁰Service D'Hematologie Et Therapie Cellulaire, Tours Cedex, France
²¹Clinical Hematology Department, Mulhouse Hospital, Mulhouse, France, Mulhouse, FRA
²²Marien Hospital, University of Düsseldorf, Düsseldorf, Germany
²³Groupe Francophone des Myelodysplasies, Hôpital St Louis/université de Paris Cité, Paris, FRA
²⁴Saint Louis Hospital, Paris, France
²⁵Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
²⁶Hopital Saint Louis, Groupe Francophone des Myelodysplasies, Paris, France, PARIS, FRA
²⁷Hopital Saint Louis, Paris, France

1840

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, MD, PhD¹, Praneeth Baratam^2,3, Anjali S. Advani, MD⁴, Abdulraheem Yacoub, MD⁵, Don A. Stevens, MD⁶, Ahmed Aribi, MD⁷^*, Ben K. Tomlinson, MD⁸, Jay Yang, MD^9,10, Pankit Vachhani, MD¹¹^*, Joseph G Jurcic, MD¹², Caspian H. Oliai, MD¹³, Jessica Liegel, MD¹⁴, Edward Pearson, MD¹⁵^*, Anna Van Rhenen, MD, PhD¹⁶^*, Marcello Rotta, MD¹⁷^*, Kapil Rathi¹⁸^*, Juan Pinelli¹⁸^*, Tara Chen, PharmD¹⁸ and Amir T. Fathi, MD¹⁹

¹James Cancer Hospital and Ohio State University, Columbus, OH
²Medical University of South Carolina, Charleston, SC
³Hollings Cancer Center, Charleston, SC
⁴Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁵University of Kansas Cancer Center, Leawood, KS
⁶Norton Cancer Institute, Norton Health Care, Louisville, KY
⁷Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
⁸University Hospitals Cleaveland Medical Center, Cleaveland, OH
⁹Karmanos Cancer Institute, Detroit, MI
¹⁰Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI
¹¹University of Alabama at Birmingham, Birmingham, AL
¹²Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
¹³Department of Medicine/Division of Hematology and Oncology, UCLA Medical Center, Los Angeles, CA
¹⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
¹⁵Texas Oncology Baylor Sammons Cancer Center, Dallas, TX
¹⁶University Medical Center Utrecht, Utrecht, Netherlands
¹⁷Colorado Blood Cancer Institute, Denver, CO
¹⁸Pfizer Inc, New York, NY
¹⁹Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA

1841

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Yazan F Madanat, MD¹, Amir T. Fathi, MD², Guillermo Garcia-Manero, MD³, Gail J. Roboz, MD⁴, Justin M. Watts, MD⁵, Gabrielle T. Prince, MD⁶^*, Praneeth Baratam, MBBS⁷, Stephane De Botton⁸^*, Anthony S. Stein, MD⁹, James M. Foran, MD¹⁰, Martha L. Arellano, MD¹¹, David Sallman, MD¹², Yuanye (Vickie) Zhang¹³^*, Stephanie M. Kapsalis¹³^*, Prapti A. Patel, MD¹³ and Courtney D. DiNardo, MD, MSc³

¹UT Southwestern Medical Center, Dallas, TX
²Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA
³University of Texas MD Anderson Cancer Center, Houston, TX
⁴Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
⁵Sylvester Cancer Center, University of Miami, Miami, FL
⁶Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
⁷Medical University of South Carolina/Hollings Cancer Center, Charleston, SC
⁸Institut Gustave Roussy, Villejuif, France
⁹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
¹⁰Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
¹¹Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA
¹²Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹³Servier Pharmaceuticals, LLC, Boston, MA

1842

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Mehmet Sevki Uyanik, MD¹^*, Guillermo Garcia-Manero, MD², Abhishek Maiti, MBBS³, Farhad Ravandi, MBBS⁴, Kelly S. Chien, MD⁵, Danielle Hammond, MD², Alexandre Bazinet, MD²^*, Heather Schneider, BSN, RN¹^*, Stephany Hendrickson⁶^*, Sherry Pierce, BSN, BA²^*, Hagop M. Kantarjian, MD², Naveen Pemmaraju, MD⁷ and Guillermo Montalban-Bravo, MD²

¹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
⁴Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, MD Anderson, Houston, TX
⁶Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX

1843

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Jeremy V. DiGennaro, DO¹, Dimitrios Drekolias, MD²^*, Najla H. Al Ali, Ms³^*, Onyee Chan, MD⁴, Seongseok Yun, MD, PhD⁵^*, Alison R. Walker, MD, MBA, MPH⁶, Zhuoer Xie, MD, MS⁵, Eric Padron, MD⁷, Jeffrey E Lancet, MD⁷, Rami S. Komrokji, MD⁸ and David Sallman, MD⁸

¹Department of Internal Medicine, The University of South Florida Morsani College of Medicine, Tampa, FL
²Department of Hematology/Oncology, University of South Florida, Morsani College of Medicine, Tampa, FL
³Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa
⁴Department of Malignant Hematology, University of Arizona, Banner University Medical Center-Tucson, Tampa, FL
⁵Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Wesley Chapel, FL
⁷Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁸Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

1844

Association between Targeted Therapy and Survival in Patients with MDS

Pierantonio Russo, MD¹^*, Ramaa Nathan²^*, Daniel Pfeffer²^* and Alex Moore²^*

¹Corporate Medical, Eversana, Cherry Hill, NJ
²Data Science, Eversana, Kansas City, KS

1845

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1^del5q): Outcomes and Response to Treatment

Rami S. Komrokji, MD¹, Zaker I. Schwabkey, MD¹, Najla H. Al Ali, Ms²^*, Luis E. Aguirre, MD³, Maximilian Stahl, MD⁴, Somedeb Ball, MD⁵, Emily F. Mason, MD, PhD⁶^*, Michael R. Savona, MD⁷, Valeria Santini, MD⁸, Angela Consagra, MD⁹^*, Uwe Platzbecker, MD¹⁰, Anne Sophie Kubasch, MD¹¹, Yazan F Madanat, MD¹², Pierre Fenaux, MD¹³, Lin-Pierre Zhao, MD¹⁴^*, Mikkael A. Sekeres, MD¹⁵, Namrata S. Chandhok, MD¹⁶, Matteo Giovanni Della Porta, MD¹⁷^*, Luca Lanino, MD¹⁸, Amy E. DeZern, MD¹⁹, David Sallman, MD², Zhuoer Xie, MD, MS²⁰, Eric Padron, MD¹, Koji Sasaki, MD²¹, Kensuke Takaoka, MD, MSc²², Akhil Jain, MD²¹^*, Mónica Del Rey²³^*, Maria Diez-Campelo, MD, PhD²⁴^* and Guillermo Garcia-Manero, MD²¹

¹Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
²Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana Farber Cancer Institute, Boston, MA
⁵Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
⁶Department of Pathology, Microbiology, Immunology, Vanderbilt University Medical Center, Nashville, TN
⁷Vanderbilt University Medical Center, Nashville, TN
⁸MDS Unit, Hematology, AOUC, University of Florence, Florence, Italy
⁹MDS Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
¹⁰Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
¹¹Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
¹²Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX
¹³Department of Hematology, Université de Paris, Saint-Louis Hospital, Paris, France
¹⁴Hématologie Seniors, Université Paris Cité, APHP, Hôpital Saint-Louis, Paris, France
¹⁵Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
¹⁶Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, FL
¹⁷IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
¹⁸IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
¹⁹The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
²⁰Department of Malignant Hematology, Moffitt Cancer Center, Lutz, FL
²¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²²University of Hawaii Internal Medicine Residency Program, Honolulu, HI
²³Department of Hematology, Salamanca-IBSAL University Hospital, Salamanca, Spain
²⁴University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Department of Hematology - Hospital Universitario de Salamanca, Salamanca, Spain

1845.1

Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)

Marie Sebert, MD, PhD¹^*, Uwe Platzbecker, MD², David Valcarcel Ferreiras, MD³^*, Valeria Santini⁴^*, Uma Borate, MD⁵, Stephanie M. Kapsalis⁶^*, Lorene Simonot⁷^*, Weishi Yuan⁸^*, Prapti A. Patel, MD⁶ and Guillermo Garcia-Manero, MD⁹

¹Hematology department, Saint-Louis Hospital, Paris, France
²Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
³Hospital Universitario Vall d'Hebron, Barcelona, Spain
⁴MDS Unit, Hematology, University of Florence, DMSC, AOUC, Florence, Italy
⁵Ohio State University Comprehensive Cancer Center/James Cancer Hospital Ohio State University, Columbus, OH
⁶Servier Pharmaceuticals, LLC, Boston, MA
⁷Servier International Research Institute, Gif-sur-Yvette, France
⁸Servier BioInnovation, Boston, MA
⁹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

637.P1.42 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I